Company profile
EyePoint
Committed to developing innovative therapeutics to improve the lives of people with serious retinal diseases.
- Industry
- Biotechnology Research
- Employees
- 264
- Headquarters
- Watertown, MA
- LinkedIn followers
- 19,573
- Office locations
- 1
EyePoint company summary
EyePoint is a company in the Biotechnology Research industry, headquartered in Watertown, MA. On LinkedIn the company has around 264 employees and 19,573 followers. Its listed specialties include Ophthalmology, Optometry, Eye Disease, Retinal Disease, Diabetic Macular Edema (DME).
What technology does EyePoint use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About EyePoint
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. Our lead product candidate is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining a selective and patent-protected tyrosine kinase inhibitor in next-generation bioerodible technology. Supported by robust safety and efficacy data to date, we are presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, with topline data anticipated in 2026. We have also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD the leading cause of vision loss among people 50 years of age and older in the United States. We are committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. Driven by our core values – Transformational Innovation, Unwavering Integrity, Compassionate Excellence, and Inclusive Collaboration, our team is dedicated to achieving our shared vision for the future and bettering the lives of patients, caregivers and healthcare professionals. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Specialties
Where is EyePoint located?
EyePoint lists 1 location.
Compare companies similar to EyePoint
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
EyePoint eyepoint.bio | Biotechnology Research | 264 | - | Watertown, MA |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about EyePoint
What does EyePoint do?
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. Our lead product candidate is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining a selective and patent-protected tyrosine kinase inhibitor in next-generation bioerodible technology. Supported by robust safety and efficacy data to date, we are presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, with topline data anticipated in 2026. We have also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD the leading cause of vision loss among people 50 years of age and older in the United States. We are committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. Driven by our core values – Transformational Innovation, Unwavering Integrity, Compassionate Excellence, and Inclusive Collaboration, our team is dedicated to achieving our shared vision for the future and bettering the lives of patients, caregivers and healthcare professionals. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
How many employees does EyePoint have?
EyePoint has around 264 employees on LinkedIn.
Where is EyePoint headquartered?
EyePoint is headquartered in Watertown, MA.
Build a lead list from companies like EyePoint
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.